Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CGEN vs VCYT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEN Captures Overall Composite Edge (47.1 HOLD vs 48.0 HOLD), While VCYT Leads 4–2 on Growth & Valuation Pillars

CGEN Overall Winner 6-Pillar Tally: CGEN 2 – 4 VCYT Matrix Metrics: CGEN 8 – 2 VCYT

As of Nov 17, 2026, Compugen Ltd (CGEN) captures the overall head-to-head institutional edge over Veracyte, Inc. (VCYT) on higher Unified Composite conviction (47.1/100 HOLD vs. 48.0/100 HOLD) after splitting the core matrix 8–2 (led by Valuation Multiples, Profitability & Quality), while VCYT wins 4–2 across the 6-pillar growth and valuation breakdown. CGEN trades at $2.02 (12.4x Forward P/E, 41.3% operating margin) versus VCYT at $24.23 (15.3x Forward P/E, 15.0% operating margin).

  • Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 15.0% operating margin) and revenue trajectory (+102.1% vs. +15.1% YoY).
  • Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGEN vs VCYT
CGEN NASDAQ Head-to-Head Winner
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $198.9M
TTM Revenue $76M
Forward P/E 12.4x
Beta / 30D Vol 1.44β · 62% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $2.02 · SMA50: $2.18
VCYT NASDAQ
Veracyte, Inc.
Services-Medical Laboratories
$24.23
+0.92% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 2.98β · 194% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $38.16 · SMA50: $41.43

6-Pillar Scorecard Institutional Category Breakdown (CGEN 2 – 4 VCYT)

Columns: Metric · CGEN · VCYT
1. Valuation Multiples CGEN
Forward P/E 12.4x 15.3x
Trailing P/E 5.4x 15.8x
PEG Ratio 1.29x N/M
EV / Revenue 2.6x 3.1x
2. Growth & Scale VCYT
Revenue Growth (YoY) +102.1% +15.1%
Earnings Growth (YoY) +0.0% +58.3%
TTM Revenue (USD) $76M $582M
Market Cap $198.9M $2.0B
3. Profitability & Quality CGEN
Gross Margin 86.2% 74.2%
Operating Margin 41.3% 15.0%
Net Profit Margin 47.9% 21.8%
Return on Equity (ROE) 57.2% 9.4%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) $32M EBITDA $162M
Cash Flow Margin 41.9% EBITDA Mgn 27.8%
Net Cash / Leverage $4.3M Net Cash $159M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VCYT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 89.7% (57th %ile) 197.3% (47th %ile)
Put/Call OI Skew N/A 27.31x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat VCYT
OpEx & R&D Intensity 44.9% of Rev ($34M) 59.2% of Rev ($344M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGEN (8) vs VCYT (2)
Institutional Metric CGEN VCYT Criterion Row Edge
Market Capitalization
Scale
$198.9M $2.0B Larger Scale VCYT
Trailing P/E Ratio
Valuation
5.4x 15.8x Lower Multiple CGEN
Forward P/E Ratio
Valuation
12.4x 15.3x Lower Multiple CGEN
Revenue Growth (YoY)
Growth
+102.1% +15.1% Higher Growth CGEN
Operating Margin (TTM)
Profitability
41.3% 15.0% Higher Margin CGEN
Net Profit Margin
Profitability
47.9% 21.8% Higher Margin CGEN
Return on Equity (ROE)
Capital Efficiency
57.2% 9.4% Higher ROE CGEN
52-Week Range Position
Momentum
33% ($1–$3) 6% ($22–$61) Stronger Trend CGEN
Beta / 30D Volatility
Risk Regime
1.44β · 62% Vol 2.98β · 194% Vol Lower Realized Risk CGEN
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$76M $582M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
86.2% 74.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.29x PEG · 2.6x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$32M EBITDA ($4.3M Net Cash) $162M ($159M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGEN +47.22 pp
CGEN: +2.54% · VCYT: -44.68%
3M Horizon CGEN +25.36 pp
CGEN: -17.21% · VCYT: -42.57%
6M Horizon CGEN +15.87 pp
CGEN: -26.01% · VCYT: -41.88%
1Y Horizon CGEN +61.59 pp
CGEN: +23.17% · VCYT: -38.42%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CGEN Revenue VCYT Revenue CGEN Op. Margin VCYT Op. Margin Margin Leader
FY2018 $20M $90M -130.5% -24.2% VCYT
FY2019 N/A $120M N/A -12.6% VCYT
FY2020 $0M $120M -1574.8% -30.1% VCYT
FY2021 $10M $220M -584.6% -37.3% VCYT
FY2022 $10M $300M -471.7% -13.9% VCYT
FY2023 $30M $360M -38.8% -23.8% VCYT
FY2024 $30M $450M -53.4% 3.6% VCYT
FY2025 $70M $520M 43.1% 11.2% CGEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGEN BREAKDOWN
143d in phase · OBV NEUTRAL
Current IV 89.7%
IV Percentile 57th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCYT BREAKDOWN
100d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 27.31x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $198.9M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 44.9% of Rev ($34M)
90D Engineering Disclosures 0 Published
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published

Investor FAQ CGEN vs VCYT Key Questions & Quantitative Answers

As of Nov 17, 2026, Compugen Ltd (CGEN) captures the overall head-to-head institutional edge over Veracyte, Inc. (VCYT) on higher Unified Composite conviction (47.1/100 HOLD vs. 48.0/100 HOLD) after splitting the core matrix 8–2 (led by Valuation Multiples, Profitability & Quality), while VCYT wins 4–2 across the 6-pillar growth and valuation breakdown. CGEN trades at $2.02 (12.4x Forward P/E, 41.3% operating margin) versus VCYT at $24.23 (15.3x Forward P/E, 15.0% operating margin). Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 15.0% operating margin) and revenue trajectory (+102.1% vs. +15.1% YoY). Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCYT leads the Growth & Scale pillar: CGEN posts +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin), compared with VCYT at +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGEN cumulative revenue shifted +250.0% while VCYT shifted +477.8%. In operating R&D and SG&A reinvestment, CGEN deploys 44.9% of Rev ($34M) (0 90-day corporate R&D disclosures) versus 59.2% of Rev ($344M) (0 disclosures) for VCYT.

CGEN screens cheaper on headline valuation multiples. CGEN trades at 12.4x Forward P/E, 5.4x Trailing P/E, 1.29x PEG, and 2.6x EV/Revenue (41.9% EBITDA margin), whereas VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEN (57.2% ROE) versus VCYT (9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk). By comparison, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 27.31x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.98β · 194% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.